Myelo 001

Drug Profile

Myelo 001

Alternative Names: Imidazolyl ethanamide pentandioic acid; Ingavirin; Myelo001; Vitaglutam

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Valenta Pharmaceuticals
  • Developer Myelo Therapeutics; Valenta Pharmaceuticals
  • Class Antivirals; Imidazoles; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Granulocyte stimulants; Haematopoiesis stimulants; Neutrophil stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neutropenia; Viral infections

Most Recent Events

  • 01 Nov 2017 Myelo Therapeutics completes the phase II MyeloConcept trial for Neutropenia (Chemotherapy-induced) in Germany (PO) (NCT02692742)
  • 04 Oct 2017 Myelo Therapeutics completes enrolment in the phase II MyeloConcept trial for Neutropenia (Chemotherapy-induced) in Germany (NCT02692742)
  • 08 Aug 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top